Last quarter (Q3 2023), Enzon Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Enzon Pharmaceuticals's net income was $-210.00K. See Enzon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 26.00K	$ 26.00K	$ 701.00K	$ 52.00K	$ 207.00K	$ 6.92M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 26.00K	$ 26.00K	$ 701.00K	-	-	-
Operating Expense	$ 1.06M	$ 1.06M	$ 1.17M	$ 1.36M	$ 1.18M	$ 1.06M
Operating Income	$ -1.04M	$ -1.03M	$ -469.00K	$ -1.30M	$ -973.00K	$ 5.86M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -346.00K	$ -646.00K	$ -7.00K	$ 1.00K	-	-
Pretax Income	$ 929.00K	$ -386.00K	$ -462.00K	$ -1.30M	$ -973.00K	$ 5.86M
Tax Provision	$ -105.00K	$ -200.00K	$ 7.00K	$ 7.00K	$ 6.00K	$ 6.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -241.00K	$ -1.46M	$ -2.49M	$ -1.77M	$ -979.00K	$ 5.85M
Basic EPS	$ 0.01	$ -0.02	$ -0.03	$ -0.03	$ -0.02	$ 0.13
Diluted EPS	$ 0.01	$ -0.02	$ -0.03	$ -0.03	$ -0.02	$ 0.13
Basic Average Shares	$ 74.44M	$ 74.22K	$ 74.22K	$ 51.10M	$ 44.22M	$ 44.22M
Diluted Average Shares	$ 74.44M	$ 74.22K	$ 74.22K	$ 51.10M	$ 44.22M	$ 44.22M
Dividend Per Share	-	-	-	$ 0.00	$ 0.12	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.06M	$ 1.06M	$ 1.17M	$ 1.36M	$ 1.18M	$ 1.06M
Net Income From Continuing And Discontinued Operation	$ 1.03M	$ -186.00K	$ -469.00K	$ -1.31M	$ -979.00K	$ 5.85M
Normalized Income	$ 499.28K	$ -586.00K	-	$ -1.31M	$ -979.00K	$ 5.85M
Interest Expense	-	-	-	-	-	-
EBIT	$ 929.00K	$ -386.00K	$ -462.00K	$ -1.30M	$ -973.00K	$ 5.86M
EBITDA	$ 297.00K	$ -386.00K	$ -462.00K	$ -1.30M	$ -973.00K	$ 5.86M

Currency in USD

Enzon Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing